AI-CVD vs Viz HCM
AI Verdict
Choose AI-CVD if…
Choose AI-CVD if your institution aims to leverage existing CT scan data for opportunistic, broad-spectrum screening of cardiovascular and multisystem diseases without additional imaging or workflow disruption. This tool is ideal for identifying hidden risks like coronary artery calcium, aortic valve calcification, and abnormal cardiac chamber volumes from scans already performed for other indications.
View AI-CVD →Choose Viz HCM if…
Choose Viz HCM if your primary goal is the rapid, real-time detection of suspected Hypertrophic Cardiomyopathy (HCM) directly from ECG analysis, coupled with intelligent care coordination. This solution is best suited for streamlining the diagnostic pathway and ensuring timely intervention for patients with this specific cardiac condition, integrating seamlessly into emergency and cardiology workflows.
View Viz HCM →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Viz HCMViz HCM offers a more active and integrated user experience with mobile-based alerts and real-time access to echocardiogram reports on various devices, streamlining care coordination for multidisciplinary teams. While AI-CVD emphasizes minimal workflow disruption by leveraging existing CT scans, Viz HCM's features suggest a more dynamic and accessible tool for clinical teams.
Clinical Value
Viz HCMViz HCM demonstrates a profound clinical impact by significantly reducing the diagnosis time for Hypertrophic Cardiomyopathy (HCM), a condition where nearly 85% of patients are undiagnosed or misdiagnosed. It boasts extensive real-world evidence and over 100 peer-reviewed studies supporting its efficacy in identifying new HCM cases and re-engaging patients. While AI-CVD offers broad opportunistic screening for multiple conditions, Viz HCM's focused and proven impact on a high-stakes, often-missed disease gives it an edge in demonstrated clinical value.
Pricing & Value
Viz HCMViz HCM provides greater transparency in its pricing model, stating it is subscription-based and highlighting available CMS reimbursement for specific CPT codes with a national payment rate. This clear path to reimbursement offers significant value to healthcare systems. AI-CVD, in contrast, only states 'contact for pricing,' offering no immediate insight into cost or potential for reimbursement.
Enterprise Readiness
Viz HCMViz HCM explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA) in place, with its platform integrated into hospital IT systems, including major EHRs like Epic and Cerner. It is deployed in 2,000 hospitals across the United States, indicating a robust and proven enterprise footprint. While AI-CVD mentions cloud deployment and HIPAA-compliant security practices, Viz HCM's widespread adoption and explicit integrations demonstrate superior enterprise readiness.
Innovation
TieBoth tools exhibit significant innovation in their respective areas. AI-CVD is innovative for being the 'most comprehensive FDA-cleared opportunistic screening platform' that extracts a wide array of multi-system biomarkers from existing CT scans without workflow disruption. Viz HCM is innovative as the 'first and only FDA-cleared AI algorithm' for HCM, creating a new regulatory category and pioneering real-time ECG analysis with intelligent care coordination. Their innovative approaches address different, yet critical, needs in healthcare.
Support & Docs
Viz HCMViz HCM provides a well-documented support infrastructure, including a 'Help Center,' 'Customer Resources,' 'User Guides,' 'Viz Academy,' and 24/7/365 urgent phone support. This indicates a comprehensive approach to customer assistance and training. Information regarding specific support and documentation for AI-CVD is not readily available in the provided facts or search results, suggesting a less transparent or extensive offering.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AI-CVD | Viz HCM |
|---|---|---|
| Name | AI-CVD | Viz HCM |
| Company | HeartLung Corporation | Viz.ai |
| Description | FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. | FDA-cleared AI tool that uses real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy (HCM) and coordinate cardiac care, significantly reducing diagnosis time. |
| Primary Modality | CT scans | ECG analysis |
| Key Features | Automated CT-derived anatomical and density-based measurements, Opportunistic screening from existing chest and abdominal CT scans, No additional imaging, radiation, contrast, or workflow disruption, Coronary Artery Calcium (CAC) scoring, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), Epicardial fat volumetry, Aorta and pulmonary artery sizing | AI-powered ECG analysis for Hypertrophic Cardiomyopathy (HCM) detection, Real-time disease detection from electrocardiograms, Mobile-based alerts and notifications to multidisciplinary care teams, Automated direction of patients to appropriate care specialists, Reduces time to diagnosis and treatment for HCM, Streamlines cardiac care coordination and clinical workflows, Seamless integration with existing clinical workflows, EHR, and PACS systems, Clinically validated with extensive real-world evidence and publications |
Videos
Demos, reviews, and walkthroughs featuring AI-CVD and Viz HCM.